Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
1357
mi
from
South Burlington, VT
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
1357
mi
from
South Burlington, VT
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
1170
mi
from
Newport News, VA
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
1170
mi
from
Newport News, VA
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
1111
mi
from
Richmond, VA
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
1111
mi
from
Richmond, VA
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
1402
mi
from
Bellevue, WA
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
1402
mi
from
Bellevue, WA
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
Clinical Research Facility
1407
mi
from
Tacoma, WA
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
Clinical Research Facility
1407
mi
from
Tacoma, WA
Click here to add this to my saved trials
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated:  3/21/2018
1321
mi
from
Edmonton,
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Status: Enrolling
Updated: 3/21/2018
1321
mi
from
Edmonton,
Click here to add this to my saved trials
Influenza Vaccine Feasibility Study in Children With Persistent Asthma
Feasibility Study to Assess the Safety of Quadrivalent, Live Attenuated Influenza Vaccine (LAIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4) in Children Aged 5-11 Years With Persistent Asthma of Varied Severity (Cell Culture Quadrivalent IIV Used as Surrogate for LAIV4)
Status: Enrolling
Updated:  3/22/2018
Centers for Disease Control and Prevention
814
mi
from
Atlanta, GA
Influenza Vaccine Feasibility Study in Children With Persistent Asthma
Feasibility Study to Assess the Safety of Quadrivalent, Live Attenuated Influenza Vaccine (LAIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4) in Children Aged 5-11 Years With Persistent Asthma of Varied Severity (Cell Culture Quadrivalent IIV Used as Surrogate for LAIV4)
Status: Enrolling
Updated: 3/22/2018
Centers for Disease Control and Prevention
814
mi
from
Atlanta, GA
Click here to add this to my saved trials
Influenza Vaccine Feasibility Study in Children With Persistent Asthma
Feasibility Study to Assess the Safety of Quadrivalent, Live Attenuated Influenza Vaccine (LAIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4) in Children Aged 5-11 Years With Persistent Asthma of Varied Severity (Cell Culture Quadrivalent IIV Used as Surrogate for LAIV4)
Status: Enrolling
Updated:  3/22/2018
Duke Clinical Vaccine Unit
1050
mi
from
Durham, NC
Influenza Vaccine Feasibility Study in Children With Persistent Asthma
Feasibility Study to Assess the Safety of Quadrivalent, Live Attenuated Influenza Vaccine (LAIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4) in Children Aged 5-11 Years With Persistent Asthma of Varied Severity (Cell Culture Quadrivalent IIV Used as Surrogate for LAIV4)
Status: Enrolling
Updated: 3/22/2018
Duke Clinical Vaccine Unit
1050
mi
from
Durham, NC
Click here to add this to my saved trials
Influenza Vaccine Feasibility Study in Children With Persistent Asthma
Feasibility Study to Assess the Safety of Quadrivalent, Live Attenuated Influenza Vaccine (LAIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4) in Children Aged 5-11 Years With Persistent Asthma of Varied Severity (Cell Culture Quadrivalent IIV Used as Surrogate for LAIV4)
Status: Enrolling
Updated:  3/22/2018
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
Influenza Vaccine Feasibility Study in Children With Persistent Asthma
Feasibility Study to Assess the Safety of Quadrivalent, Live Attenuated Influenza Vaccine (LAIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4) in Children Aged 5-11 Years With Persistent Asthma of Varied Severity (Cell Culture Quadrivalent IIV Used as Surrogate for LAIV4)
Status: Enrolling
Updated: 3/22/2018
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Influenza Vaccine Feasibility Study in Children With Persistent Asthma
Feasibility Study to Assess the Safety of Quadrivalent, Live Attenuated Influenza Vaccine (LAIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4) in Children Aged 5-11 Years With Persistent Asthma of Varied Severity (Cell Culture Quadrivalent IIV Used as Surrogate for LAIV4)
Status: Enrolling
Updated:  3/22/2018
Vanderbilt Vaccine Research Program
618
mi
from
Nashville, TN
Influenza Vaccine Feasibility Study in Children With Persistent Asthma
Feasibility Study to Assess the Safety of Quadrivalent, Live Attenuated Influenza Vaccine (LAIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4) in Children Aged 5-11 Years With Persistent Asthma of Varied Severity (Cell Culture Quadrivalent IIV Used as Surrogate for LAIV4)
Status: Enrolling
Updated: 3/22/2018
Vanderbilt Vaccine Research Program
618
mi
from
Nashville, TN
Click here to add this to my saved trials
Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence
Contingency Management Plus Levodopa/Carbidopa for Treatment of Cocaine Dependence
Status: Enrolling
Updated:  3/23/2018
University of Texas Health Science Center at Houston
563
mi
from
Houston, TX
Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence
Contingency Management Plus Levodopa/Carbidopa for Treatment of Cocaine Dependence
Status: Enrolling
Updated: 3/23/2018
University of Texas Health Science Center at Houston
563
mi
from
Houston, TX
Click here to add this to my saved trials
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
1339
mi
from
San Francisco, CA
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
1339
mi
from
San Francisco, CA
Click here to add this to my saved trials
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
801
mi
from
Atlanta, GA
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
801
mi
from
Atlanta, GA
Click here to add this to my saved trials
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
196
mi
from
Kansas City, KA
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
196
mi
from
Kansas City, KA
Click here to add this to my saved trials
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
1444
mi
from
Boston, MA
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
1444
mi
from
Boston, MA
Click here to add this to my saved trials
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
1444
mi
from
Boston, MA
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
1444
mi
from
Boston, MA
Click here to add this to my saved trials
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
1393
mi
from
Lebanon, NH
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
1393
mi
from
Lebanon, NH
Click here to add this to my saved trials
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
895
mi
from
Cleveland, OH
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
895
mi
from
Cleveland, OH
Click here to add this to my saved trials
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
971
mi
from
Pittsburgh, PA
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
971
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
618
mi
from
Nashville, TN
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
618
mi
from
Nashville, TN
Click here to add this to my saved trials
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
569
mi
from
Houston, TX
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
569
mi
from
Houston, TX
Click here to add this to my saved trials
Cognitive Remediation for Cocaine Dependence
Cognitive-enhancing DA Medications for Cocaine Dependence
Status: Enrolling
Updated:  3/23/2018
Behavioral and Biomedical Sciences Building
569
mi
from
Houston, TX
Cognitive Remediation for Cocaine Dependence
Cognitive-enhancing DA Medications for Cocaine Dependence
Status: Enrolling
Updated: 3/23/2018
Behavioral and Biomedical Sciences Building
569
mi
from
Houston, TX
Click here to add this to my saved trials
Impact of Enhanced External Counterpulsation (EECP) on VO2 MAX
Impact of Enhanced External Counterpulsation (EECP) on VO2 MAX
Status: Enrolling
Updated:  3/23/2018
David Grant AF Medical Center
1310
mi
from
Travis Air Force Base, CA
Impact of Enhanced External Counterpulsation (EECP) on VO2 MAX
Impact of Enhanced External Counterpulsation (EECP) on VO2 MAX
Status: Enrolling
Updated: 3/23/2018
David Grant AF Medical Center
1310
mi
from
Travis Air Force Base, CA
Click here to add this to my saved trials
PPARγ Agonist Treatment for Cocaine Dependence
PPARγ Agonist Treatment for Cocaine Dependence
Status: Enrolling
Updated:  3/26/2018
University of Texas Health Science Center at Houston
563
mi
from
Houston, TX
PPARγ Agonist Treatment for Cocaine Dependence
PPARγ Agonist Treatment for Cocaine Dependence
Status: Enrolling
Updated: 3/26/2018
University of Texas Health Science Center at Houston
563
mi
from
Houston, TX
Click here to add this to my saved trials
ARMS-I (a Formulation of Cetylpyridinium Chloride -CPC)
Evaluation of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Orally Administered ARMS-I Administered in Healthy Adults, Aged 18-45 Years
Status: Enrolling
Updated:  3/27/2018
Promedica Health System
801
mi
from
Toledo, OH
ARMS-I (a Formulation of Cetylpyridinium Chloride -CPC)
Evaluation of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Orally Administered ARMS-I Administered in Healthy Adults, Aged 18-45 Years
Status: Enrolling
Updated: 3/27/2018
Promedica Health System
801
mi
from
Toledo, OH
Click here to add this to my saved trials
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated:  3/28/2018
Children's Hospital Colorado
400
mi
from
Aurora, CO
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated: 3/28/2018
Children's Hospital Colorado
400
mi
from
Aurora, CO
Click here to add this to my saved trials
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated:  3/28/2018
Emory University School of Medicine
803
mi
from
Atlanta, GA
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated: 3/28/2018
Emory University School of Medicine
803
mi
from
Atlanta, GA
Click here to add this to my saved trials
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated:  3/28/2018
Ann & Robert H. Lurie Children's Hospital of
611
mi
from
Chicago, IL
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated: 3/28/2018
Ann & Robert H. Lurie Children's Hospital of
611
mi
from
Chicago, IL
Click here to add this to my saved trials
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated:  3/28/2018
Riley Hospital for Children
643
mi
from
Indianapolis, IN
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated: 3/28/2018
Riley Hospital for Children
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated:  3/28/2018
University of Minneapolis Medical Center
552
mi
from
Minneapolis, MN
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated: 3/28/2018
University of Minneapolis Medical Center
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated:  3/28/2018
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated: 3/28/2018
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated:  3/28/2018
Texas Children's Hospital
572
mi
from
Houston, TX
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated: 3/28/2018
Texas Children's Hospital
572
mi
from
Houston, TX
Click here to add this to my saved trials
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated:  3/28/2018
Seattle Children's Hospital
1410
mi
from
Seattle, WA
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated: 3/28/2018
Seattle Children's Hospital
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated:  3/28/2018
Johns Hopkins School of Medicine
1149
mi
from
Baltimore, MD
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated: 3/28/2018
Johns Hopkins School of Medicine
1149
mi
from
Baltimore, MD
Click here to add this to my saved trials
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated:  3/28/2018
Hospital for Sick Children
1045
mi
from
Toronto,
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated: 3/28/2018
Hospital for Sick Children
1045
mi
from
Toronto,
Click here to add this to my saved trials
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated:  3/28/2018
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)
Status: Enrolling
Updated: 3/28/2018
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Post-operative Pain Control After Pediatric Adenotonsillectomy
Comparing Narcotics With Non-steroidal Anti-inflammatory Drugs (NSAIDS) Post-operatively in Pediatric Patients Undergoing Adenotonsillectomy
Status: Enrolling
Updated:  3/28/2018
Children's Healthcare of Atlanta (CHOA)
801
mi
from
Atlanta, GA
Post-operative Pain Control After Pediatric Adenotonsillectomy
Comparing Narcotics With Non-steroidal Anti-inflammatory Drugs (NSAIDS) Post-operatively in Pediatric Patients Undergoing Adenotonsillectomy
Status: Enrolling
Updated: 3/28/2018
Children's Healthcare of Atlanta (CHOA)
801
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluation of COPD Co-Pilot
Evaluation of COPD Co-Pilot
Status: Enrolling
Updated:  3/28/2018
University of Alabama at Birmingham
676
mi
from
Birmingham, AL
Evaluation of COPD Co-Pilot
Evaluation of COPD Co-Pilot
Status: Enrolling
Updated: 3/28/2018
University of Alabama at Birmingham
676
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated:  4/2/2018
Novartis Investigator Site
685
mi
from
Birmingham, AL
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated: 4/2/2018
Novartis Investigator Site
685
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated:  4/2/2018
Novartis Investigative Site
1154
mi
from
Fullerton, CA
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated: 4/2/2018
Novartis Investigative Site
1154
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated:  4/2/2018
Novartis Investigator Site
1102
mi
from
Clearwater, FL
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated: 4/2/2018
Novartis Investigator Site
1102
mi
from
Clearwater, FL
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated:  4/2/2018
Novartis Investigative Site
1137
mi
from
Port Orange, FL
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated: 4/2/2018
Novartis Investigative Site
1137
mi
from
Port Orange, FL
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated:  4/2/2018
Novartis Investigational Site
1111
mi
from
Tampa, FL
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated: 4/2/2018
Novartis Investigational Site
1111
mi
from
Tampa, FL
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated:  4/2/2018
Novartis Investigative Site
510
mi
from
Normal, IL
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated: 4/2/2018
Novartis Investigative Site
510
mi
from
Normal, IL
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated:  4/2/2018
Novartis Investigative Site
918
mi
from
Shelby, NC
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated: 4/2/2018
Novartis Investigative Site
918
mi
from
Shelby, NC
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated:  4/2/2018
Novartis Investigative Site
1357
mi
from
Medford, OR
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated: 4/2/2018
Novartis Investigative Site
1357
mi
from
Medford, OR
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated:  4/2/2018
Novartis Investigative Site
890
mi
from
Simpsonville, SC
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated: 4/2/2018
Novartis Investigative Site
890
mi
from
Simpsonville, SC
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated:  4/2/2018
Novartis Investigative Site
903
mi
from
Spartanburg, SC
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated: 4/2/2018
Novartis Investigative Site
903
mi
from
Spartanburg, SC
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated:  4/2/2018
Novartis Investigative Site
929
mi
from
Union, SC
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated: 4/2/2018
Novartis Investigative Site
929
mi
from
Union, SC
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated:  4/2/2018
Novartis Investigative Site
1337
mi
from
Waterbury, CT
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Status: Enrolling
Updated: 4/2/2018
Novartis Investigative Site
1337
mi
from
Waterbury, CT
Click here to add this to my saved trials